Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

453.97 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗
 
Via Benzinga
News headline image
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
How Is The Market Feeling About Alnylam Pharmaceuticals? ↗
 
Via Benzinga
News headline image
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (24 Ratings) ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
Why NASDAQ:ALNY qualifies as a high growth stock. ↗
Why ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) qualifies as a high growth stock. 
Via Chartmill
News headline image
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,300 Today ↗
 
Via Benzinga
News headline image
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (24 Ratings) ↗
 
Via Benzinga
News headline image
This Airbnb Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
News headline image
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
News headline image
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio? ↗
Eleven large-cap stocks were worst performers last week. Decline in Stars performance and sales, regulations and supply issues caused the drop. 
Via Benzinga
News headline image
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine ↗
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible... 
Via Benzinga
Topics Intellectual Property
News headline image
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.